Anti-LMP2 T cell receptor ((NB20)-4), pCDTCR1 (TCR-YC0634)

It has proved that a subset of alloreactive interactions that include allo-MHC–restricted TCR/MHC recognition events is very analogous to self-restricted TCR/MHC interactions and involves high specificity for MHC-bound peptide. NB20 bound its alloligand HLA-A2-CLG with a Kd in the range of self-restricted interactions and did not bind irrelevant HLA-A2 peptides or other class I MHC molecules, consistent with the properties of the NB20 T-cell clone and analogous to self-restricted TCRs. Use of CLG variants underlined the importance of multiple peptide residues in NB20 recognition, most of which (L5, L6, and M8) have large exposed side chains prominently positioned in the alloligand structure, indicating direct interaction. In contrast, CLG recognition was unaffected by P1 substitution in the least prominent section of CLG.

Datasheet   Add to Cart


  • Target
  • LMP2
  • Epitope
  • Format
  • Non-Modified TCR
  • Allele
  • HLA-A*02:01
  • Targeting Diseases
  • Tumor
  • Vector Name
  • pCDTCR1
  • Vector Length
  • ~ 8 kb
  • Vector Type
  • Lentiviral vector
  • TCR Clone
  • NB20
  • Host Species
  • Human


  • Introduction
  • Manipulation of T-cell allorecognition offers the prospect of powerful new therapies for hematological and solid tumors. Importantly, although a minority of tumor-associated antigens (TAAs) are truly tumor-specific, many others, including universal TAAs, are expressed to some extent on untransformed tissues and in the thymus at levels sufficient to mediate effective antigen-specific T-cell tolerance. The result is a mature repertoire of self-MHC–restricted T cells devoid of potent effector capacity targeting specific TAAs. Such effects, thought to apply to several universal TAAs, such as the tumor suppressor p53, the p53 regulator protein MDM2, Cyclin D1, and Wilms' tumor antigen WT1, contribute to poor autologous tumor immunity and represent a major hurdle in cancer immunotherapy.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry


USA: 45-1 Ramsey Road, Shirley, NY 11967, USA
Europe: Heidenkampsweg 58, 20097 Hamburg, Germany
Call us at:
USA: 1-631-381-2994
Europe: 44-207-097-1828
Fax: 1-631-207-8356

Online Inquiry

For any technical issues or products/services related questions, please leave your information below. Our team will contact you soon.

  • Verification code
    Click image to refresh the verification code.

Key Updates

Receive our latest news and insights.